Bloomsbury Genetic Therapies
A clinical-stage biotech company developing potentially curative treatments for patients suffering from rare neurological and metabolic diseases based on clinically proven gene therapy technologies.
The UK-based company was spun out of University College London and launched in October 2022 with funding from UCL Technology Fund.
Bloomsbury is building a pipeline of highly differentiated first- or best-in-class programs, with the US FDA granting Rare Pediatric Disease designation (RPDD) in July 2023 for BGT-OTCD, the company’s investigational liver-targeted gene therapy for the treatment of Ornithine transcarbamylase deficiency (OTCD).
Latest Bloomsbury Genetic Therapies News & Features
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze